Ken Griffin Burning Rock Biotech LTD Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.68 - $0.97 $8,539 - $12,181	12,558 New	12,558 $9,000
Q3 2022 Nov 14, 2022	BUY	$2.39 - $3.96 $62,154 - $102,983	26,006 New	26,006 $63,000
Q2 2022 Aug 15, 2022	SELL	$1.75 - $10.44 $50,312 - $300,150	-28,750 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$6.7 - $10.23 $816,395 - $1.25 Million	-121,850 Reduced 80.91%	28,750 $267,000
Q4 2021 Feb 14, 2022	BUY	$9.43 - $17.14 $1.11 Million - $2.01 Million	117,286 Added 352.06%	150,600 $1.44 Million
Q3 2021 Nov 15, 2021	SELL	$17.37 - $27.92 $84,574 - $135,942	-4,869 Reduced 12.75%	33,314 $596,000
Q2 2021 Aug 16, 2021	SELL	$26.14 - $37.45 $1.77 Million - $2.54 Million	-67,794 Reduced 63.97%	38,183 $1.12 Million
Q1 2021 May 17, 2021	BUY	$23.5 - $39.58 $2.49 Million - $4.19 Million	105,977 New	105,977 $2.85 Million
Q3 2020 Nov 16, 2020	SELL	$19.07 - $29.61 $381,400 - $592,200	-20,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$23.21 - $31.43 $464,200 - $628,600	20,000 New	20,000 $540,000

21.2K

Ticker BNR
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 105,188,000
Market Cap $692M
Description
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and p...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.